Matching trials
2,411 results
- AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02513563).
- Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections: Complete Statistical AnalysisIndependent statistical analysis of Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04884308).
- BARI-COVIDAn independent statistical analysis of the BARI-COVID phase 2/3 study of baricitinib in symptomatic patients infected by COVID-19, including its crossover design, ICU-transfer endpoint, planned analysis, and statistical interpretation.
- Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus: Complete Statistical AnalysisIndependent statistical analysis of Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05188521).
- Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00410059).
- BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326495).
- BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BBTIndependent statistical analysis of Beneficial Bacteria Treatment for Autism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02504554).
- BCC-RAD-13Independent statistical analysis of Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BE ACTIVE 2Independent statistical analysis of A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BEACONIndependent statistical analysis of HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BEGINIndependent statistical analysis of A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease: primary endpoint results, effect estimate with confidence interval,…
- BEGSIndependent statistical analysis of Benralizumab for Eosinophilic Gastritis (BEGS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03473977).
- Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04676360).
- Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin:…
- BELLE-4Independent statistical analysis of A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation: primary endpoint results,…
- Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin’s Lymphoma(NHL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00426855).
- Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705250).
- Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Berinert (C1INH) vs Placebo for DGF/IRI: Complete Statistical AnalysisIndependent statistical analysis of Berinert (C1INH) vs Placebo for DGF/IRI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04696146).
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BESPOKEIndependent statistical analysis of A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BESTFITIndependent statistical analysis of BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01903265).
- Beta-blockers in Pulmonary Arterial Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Beta-blockers in Pulmonary Arterial Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02507011).
- BevacizumabIndependent statistical analysis of A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00401817).
- Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01125046).
- Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00055692).
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BFFIndependent statistical analysis of Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03496545).
- BI 10773 add-on to Metformin in Patients With Type 2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of BI 10773 add-on to Metformin in Patients With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BIANCAIndependent statistical analysis of Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BiBETIndependent statistical analysis of Optimized Biventricular Pacing Allograft Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01290822).
- BIBSIndependent statistical analysis of Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02188459).
- Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: Complete Statistical AnalysisIndependent statistical analysis of Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…